Effectiveness of the 2013 and 2014 Southern Hemisphere influenza vaccines against laboratory-confrmed influenza in young children using a test-negative design, Bangkok, Thailand

Pediatric Infectious Disease Journal

Volumn 35, Issue 10, 2016, Pages e318-e325

  Kittikraisak, Wanitchaya ^a   Suntarattiwong, Piyarat ^a   Ditsungnoen, Darunee ^a   Klungthong, Chonticha ^b   Fernandez, Stefan ^b   Yoon, In Kyu ^c   Lindblade, Kim ^a,d   Dawood, Fatimah S ^d   Olsen, Sonja J ^d   Chotpitayasunondh, Tawee ^a  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^c International Vaccine Institute   (South Korea)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Children; Effectiveness; Influenza; Thailand; Vaccination

Indexed keywords

INFLUENZA VACCINE; OSELTAMIVIR;

ARTICLE; CHILD; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; HUMAN; INFANT; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA VACCINATION; LABORATORY CONFIRMED INFLUENZA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NOSE SMEAR; OUTPATIENT DEPARTMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN HEMISPHERE; THAILAND; THROAT CULTURE; GENETICS; IMMUNOLOGY; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; PREVENTIVE HEALTH SERVICE; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VACCINATION; VIROLOGY;

CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; THAILAND; TREATMENT OUTCOME; VACCINATION;

EID: 84974806795     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000001280     Document Type: Article

References (40)

1. Vaccines against Influenza WHO position paper-November 2012. Wkly Epidemiol Rec. 2012;87:461-476.
2. Mostaço-Guidolin LC, Towers SM, Buckeridge DL, et al. Age distribu-tion of infection and hospitalization among Canadian First Nations populations during the 2009 H1N1 pandemic. Am J Public Health. 2013;103:e39-e44.
3. Katz MA, Lebo E, Emukule G, et al. Epidemiology, seasonality, and burden of Influenza and Influenza-like illness in urban and rural Kenya, 2007-2010. J Infect Dis. 2012;206(suppl 1):S53-S60.
4. Muyembe Tamfum JJ, Nkwembe E, et al. Sentinel surveillance for infu-enza-like illness, severe acute respiratory illness, and laboratory-confrmed Influenza in Kinshasa, Democratic Republic of Congo, 2009-2011. J Infect Dis. 2012;206(suppl 1):S36-S40.
5. Radin JM, Katz MA, Tempia S, et al. Influenza surveillance in 15 countries in Africa, 2006-2010. J Infect Dis. 2012;206(suppl 1):S14-S21.
6. Nair H, Brooks WA, Katz M, et al. Global burden of respiratory infections due to seasonal Influenza in young children: a systematic review and meta-analysis. Lancet. 2011;378:1917-1930.
7. Grohskopf LA, Sokolow LZ, Olsen SJ, et al. Prevention and control of Influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 Influenza season. MMWR Morb Mortal Wkly Rep. 2015;64:818-825.
8. rd WHO informal consultation for improving Influenza vaccine virus selection held at WHO headquarters, Geneva, Switzerland, 1-3 April 2014. Vaccine. 2015;33:4368-4382.
9. Belshe RB, Coelingh K, Ambrose CS, et al. Effcacy of live attenuated infu-enza vaccine in children against Influenza B viruses by lineage and antigenic similarity. Vaccine. 2010;28:2149-2156.
10. Carrat F, Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine. 2007;25:6852-6862.
11. Sullivan SG, Feng S, Cowling BJ. Potential of the test-negative design for measuring Influenza vaccine effectiveness: a systematic review. Expert Rev Vaccines. 2014;13:1571-1591.
12. Jackson ML, Nelson JC. The test-negative design for estimating Influenza vaccine effectiveness. Vaccine. 2013;31:2165-2168.
13. Foppa IM, Haber M, Ferdinands JM, et al. The case test-negative design for studies of the effectiveness of Influenza vaccine. Vaccine. 2013;31:3104-3109.
14. Simmerman JM, Chittaganpitch M, Levy J, et al. Incidence, seasonality and mortality associated with Influenza pneumonia in Thailand: 2005-2008. PLoS One. 2009;4:e7776.
15. Baggett HC, Chittaganpitch M, Thamthitiwat S, et al. Incidence and epide-miology of hospitalized Influenza cases in rural Thailand during the infu-enza A (H1N1)pdm09 pandemic, 2009-2010. PLoS One. 2012;7:e48609.
16. Saha S, Chadha M, Al Mamun A, et al. Influenza seasonality and vaccination timing in tropical and subtropical areas of southern and south-eastern Asia. Bull World Health Organ. 2014;92:318-330.
17. Chittaganpitch M, Supawat K, Olsen SJ, et al. Influenza viruses in Thailand: 7 years of sentinel surveillance data, 2004-2010. Influenza Other Respir Viruses. 2012;6:276-283.
18. World Health Organization. WHO recommendations on the composition of Influenza virus vaccines. Geneva, Switzerland: World Health Organization, 2016. Available at: http://www.who.int/Influenza/vaccines/virus/recommen-dations/en/. Accessed January 25, 2016.
19. WHO Collaborating Centre for Influenza. CDC protocol of real-time RTPCR for Influenza A (H1N1). Atlanta, GA: 2009. Available at: http://www.who.int/csr/resources/publications/swinefu/CDCRealtimeRTPCR- SwineH1Assay-2009-20090430.pdf. Accessed January 25, 2016.
20. Centers for Disease Control and Prevention. Prevention and control of Influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)-United States, 2012-2013 Influenza season. Morb Mortal Wkly Rep. 2012;61:613-618.
21. Fujieda M, Maeda A, Kondo K, et al. Influenza vaccine effectiveness and confounding factors among young children. Vaccine. 2008;26:6481-6485.
22. Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal Influenza immunization in mothers and infants. N Engl J Med. 2008;359:1555-1564.
23. Tandon SS. Effectiveness of maternal Influenza immunization. N Engl J Med. 2009;360:537-538; author reply 538.
24. Hailpern SM, Visintainer P F. Odds ratios and logistic regression: further examples of their use and interpretation. Stata J. 2003;3(3):213-225.
25. Exchange Rates UK. Full USD THB exchange rate history. United Kingdom: Exchange Rates UK; 2016. Available at: http://www.exchanger-ates.org.uk/USD-THB-exchange-rate-history-full.html. Accessed January 19, 2016.
26. Statistical Forecasting Bureau. Average monthly income per household: 1996-2013. Bangkok, Thailand: National Statistical Offce; 2013. Available at: http://service.nso.go.th/nso/web/statseries/statseries11.html. Accessed November 9, 2015.
27. Cheng AC, Dwyer DE, Holmes M, et al. Influenza epidemiology, vaccine coverage and vaccine effectiveness in sentinel Australian hospitals in 2013: the Influenza Complications Alert Network. Commun Dis Intell Q Rep. 2014;38:E143-E149.
28. Turner N, Pierse N, Bissielo A, et al; SHIVERS Investigation Team. Effectiveness of seasonal trivalent inactivated Influenza vaccine in preventing Influenza hospitalisations and primary care visits in Auckland, New Zealand, in 2013. Euro Surveill. 2014;19(34).
29. Kittikraisak W, Suntarattiwong P, Levy J, et al. Influenza vaccination coverage and effectiveness in young children in Thailand, 2011-2013. Influenza Other Respir Viruses. 2015;9:85-93.
30. Levy JW, Simasathien S, Watanaveeradej V, et al. Influenza vaccine effectiveness in the tropics: moderate protection in a case test-negative analysis of a hospital-based surveillance population in Bangkok between August 2009 and January 2013. PLoS One. 2015;10:e0134318.
31. Souty C, Blanchon T, Bonmarin I, et al. Early estimates of 2014/15 seasonal Influenza vaccine effectiveness in preventing Influenza-like illness in general practice using the screening method in France. Hum Vaccin Immunother. 2015;11:1621-1625.
32. Centers for Disease Prevention and Control. CDC health advisory regarding the potential for circulation of drifted Influenza A (H3N2) viruses. Atlanta, GA: Centers for Disease Prevention and Control; 2014.
33. Broberg E, Snacken R, Adlhoch C, et al; WHO European Region and the European Influenza Surveillance Network. Start of the 2014/15 Influenza season in Europe: drifted Influenza A(H3N2) viruses circulate as dominant subtype. Euro Surveill. 2015;20(4).
34. Pebody RG, Warburton F, Ellis J, et al. Low effectiveness of seasonal Influenza vaccine in preventing laboratory-confrmed Influenza in primary care in the United Kingdom: 2014/15 mid-season results. Euro Surveill. 2015;20:21025.
35. Skowronski D, Chambers C, Sabaiduc S, et al. Interim estimates of 2014/15 vaccine effectiveness against Influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015. Euro Surveill. 2015;20(4):1-18.
36. Owusu JT, Prapasiri P, Ditsungnoen D, et al. Seasonal Influenza vaccine coverage among high-risk populations in Thailand, 2010-2012. Vaccine. 2015;33:742-747.
37. Population Projections of Thailand 2000-2030. National Economic and Social Development Board of Thailand. Bangkok, Thailand: Offce of the National Economic and Social Development Board; 2007 Available at: http://www.nesdb.go.th/temp-social/pop.zip. Accessed January 25, 2016.
38. Brown C, Clayton-Boswell H, Chaves SS, et al; New Vaccine Surveillance Network (NVSN). Validity of parental report of Influenza vaccination in young children seeking medical care. Vaccine. 2011;29:9488-9492.
39. Weinberg GA, Erdman DD, Edwards KM, et al; New Vaccine Surveillance Network Study Group. Superiority of reverse-transcription polymerase chain reaction to conventional viral culture in the diagnosis of acute respiratory tract infections in children. J Infect Dis. 2004;189:706-710.
40. Thai National Influenza Center. National Institute of Health. Nonthaburi, Thailand: Thai National Influenza Center; 2015. Available at: http://www. thainihnic.org/Influenza/main.php?option=report. Accessed January 25, 2016.